News

Supreme Court: Human genes cannot be patented


 

Private companies do not have the right to patent human genes, the U.S. Supreme Court has ruled.

In a unanimous decision issued on June 13, the high court ruled that a naturally occurring DNA segment is a "product of nature" and is not eligible for a patent simply because it has been isolated. But the court also ruled that synthetically created DNA known as complementary DNA (cDNA) can be granted a patent.

In Association for Molecular Pathology et al. v. Myriad Genetics, the high court considered the validity of patents held by Utah-based Myriad Genetics for the BRCA1 and BRCA2 genes, which are associated with an increased risk of breast and ovarian cancer.

Scientists at Myriad Genetics uncovered the location and sequence of the BRCA1 and BRCA2 genes in the mid-1990s. Since then, they have held the exclusive rights to the diagnostic testing for the mutations. But critics say the monopoly on testing held by Myriad is bad for patients because the test is expensive and they have no alternative confirmatory test.

"It is undisputed that Myriad did not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 genes," Justice Clarence Thomas wrote in the court’s opinion. "Myriad’s principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes within chromosomes 17 and 13."

The justices concluded that simply isolating genes and the information they encode from the surrounding genetic material is insufficient for a patent. However, cDNA are not naturally occurring so tests using that technology can be patented.

The American Medical Association, which filed an amicus brief in support of invalidating the Myriad patents, praised the Court’s decision.

“Removing the patents on the building blocks of life ensures that scientific discovery and medical care based on insights into human DNA will remain freely accessible and widely disseminated, not hidden behind a vast thicket of exclusive rights,” Dr. Jeremy A. Lazarus, AMA president, said in a statement.

The American Civil Liberties Union, which joined the suit against Myriad, said the decision brings down a major barrier to patient care and medical innovation. "Because of this ruling, patients will have greater access to genetic testing and scientists can engage in research on these genes without fear of being sued," Sandra Park, senior staff attorney with the ACLU Women’s Rights Project, said in a statement.

The Supreme Court’s decision comes too late to have much of a practical impact on BRCA1 and BRCA2 testing, since Myriad’s 20-year exclusivity on the patents in dispute all expire by 2015.

mschneider@frontlinemedcom.com

On Twitter @MaryEllenNY

Recommended Reading

CMS offers $1 billion for health innovators
MDedge Neurology
Ramping up comparative effectiveness research
MDedge Neurology
EHR use reaches 'tipping point'
MDedge Neurology
CDC urges doctors to help patients quit smoking
MDedge Neurology
Study supports laws requiring cyclists to wear helmets
MDedge Neurology
House Republicans proffer SGR fix legislation
MDedge Neurology
Feds turn to crowdsourcing for health care answers
MDedge Neurology
Few physicians use EHRs to exchange data
MDedge Neurology
HHS fundraising probe expands: The Policy & Practice Podcast
MDedge Neurology
New HIPAA requirements
MDedge Neurology